Chinese General Practice ›› 2024, Vol. 27 ›› Issue (33): 4139-4146.DOI: 10.12114/j.issn.1007-9572.2024.0055
Special Issue: 内分泌代谢性疾病最新文章合辑; 肥胖最新文章合辑
• Original Research • Previous Articles Next Articles
Received:
2024-03-21
Revised:
2024-05-27
Published:
2024-11-20
Online:
2024-08-08
Contact:
FENG Wenhuan
通讯作者:
冯文焕
作者简介:
作者贡献:
张冰青负责临床数据收集、整理、分析,并撰写论文初稿;胡馨云负责绘制图表并协助统计分析;欧阳煜钦负责临床资料质量把控,协助初稿撰写;向心月协助参与论文内容及格式修改;汤文娟完善论文的审校;冯文焕提出研究思路,设计研究方案,完善论文最终内容及审校,并对论文负责。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0055
指标 | 训练集(n=633) | 验证集(n=272) | Z(χ2)值 | P值 |
---|---|---|---|---|
年龄[M(Q1,Q3),岁] | 59(53,63) | 58(51,64) | -0.232 | 0.817 |
性别[例(%)] | 0.300a | 0.584 | ||
男 | 343(54.2) | 142(52.2) | ||
女 | 290(45.8) | 130(47.8) | ||
肌肉量减少[例(%)] | 278(43.9) | 105(38.6) | 2.202a | 0.138 |
病程[M(Q1,Q3),年] | 10(4,15) | 9(5,15) | -0.928 | 0.353 |
BMI<23.5 kg/m2[例(%)] | 292(46.1) | 117(43.0) | 0.745a | 0.388 |
SBP[M(Q1,Q3),mmHg] | 133(119,146) | 135(124,146) | -1.232 | 0.218 |
DBP[M(Q1,Q3),mmHg] | 81(74,89) | 82(75,88) | -0.547 | 0.584 |
ALT[M(Q1,Q3),U/L] | 17.5(13.6,24.3) | 18.9(13.4,26.8) | -0.993 | 0.321 |
AST[M(Q1,Q3),U/L] | 16.5(14.1,20.9) | 17.4(14.1,22.4) | -1.397 | 0.162 |
GGT[M(Q1,Q3),U/L] | 24.5(16.9,37.7) | 25.4(18.8,38.7) | -1.402 | 0.161 |
HbA1c[M(Q1,Q3),%] | 8.6(7.2,10.2) | 8.9(7.3,10.2) | -1.135 | 0.256 |
FBG[M(Q1,Q3),mmol/L] | 7.9(6.3,9.9) | 7.8(6.5,9.8) | -0.456 | 0.648 |
FINS[M(Q1,Q3),μU/mL] | 5.5(3.4,8.9) | 5.5(3.4,8.8) | -0.012 | 0.990 |
HOMA-IR[M(Q1,Q3)] | 2.0(1.2,3.3) | 2.0(1.2,3.2) | -0.029 | 0.977 |
TG[M(Q1,Q3),mmol/L] | 1.3(1.0,1.9) | 1.3(0.9,1.8) | -0.552 | 0.581 |
TC[M(Q1,Q3),mmol/L] | 4.5(3.8,5.4) | 4.6(3.8,5.4) | -0.899 | 0.369 |
HDL-C[M(Q1,Q3),mmol/L] | 1.2(1.0,1.4) | 1.2(1.0,1.4) | -0.210 | 0.834 |
LDL-C[M(Q1,Q3),mmol/L] | 2.7(2.0,3.4) | 2.7(2.1,3.5) | -0.821 | 0.412 |
UA[M(Q1,Q3),μmol/L] | 305.5(251.0,371.3) | 309.0(259.0,371.0) | -0.114 | 0.909 |
Scr[M(Q1,Q3),μmol/L] | 56.0(45.0,66.0) | 57.0(49.3,66.8) | -1.617 | 0.106 |
eGFR[M(Q1,Q3),mL·min-1·(1.73 m2)-1] | 124.8(104.8,146.2) | 120.6(103.8,140.6) | -1.021 | 0.307 |
CRP[M(Q1,Q3),mg/L] | 2.9(2.1,3.9) | 2.7(2.0,3.8) | -1.088 | 0.277 |
OCN[M(Q1,Q3),ng/mL] | 12.2(9.5,15.6) | 12.0(9.4,15.5) | -0.104 | 0.917 |
β-CTX[M(Q1,Q3),ng/mL] | 0.4(0.3,0.5) | 0.4(0.3,0.5) | -0.208 | 0.835 |
P1ND[M(Q1,Q3),ng/mL] | 37.1(27.8,49.1) | 36.8(29.5,49.0) | -0.377 | 0.706 |
25(OH)D3[M(Q1,Q3),ng/mL] | 19.7(15.4,24.5) | 19.6(15.1,24.5) | -0.172 | 0.864 |
ALB[M(Q1,Q3),g/L] | 42.1(40.3,43.5) | 42.2(40.6,43.6) | -1.322 | 0.186 |
Hb[M(Q1,Q3),g/L] | 141(131,151) | 143(133,152) | -1.607 | 0.108 |
UACR[M(Q1,Q3),mg/g] | 12.0(6.7,28.7) | 11.7(7.4,23.9) | -0.248 | 0.804 |
内脏脂肪面积[M(Q1,Q3),cm2] | 79.6(65.1,97.8) | 78.6(64.5,95.7) | -0.540 | 0.589 |
TSH[M(Q1,Q3),mU/L] | 1.7(1.2,2.5) | 1.7(1.2,2.4) | -0.579 | 0.572 |
FT3[M(Q1,Q3),pmol/L] | 4.4(4.0,4.8) | 4.5(4.1,4.9) | -1.554 | 0.119 |
FT4[M(Q1,Q3),pmol/L] | 17.1(15.6,19.0) | 17.2(15.7,19.0) | -0.703 | 0.482 |
GH[M(Q1,Q3),μg/L] | 0.4(0.1,1.2) | 0.4(0.1,1.2) | -0.987 | 0.324 |
ACTH(8:00)[M(Q1,Q3),pmol/L] | 4.9(3.4,6.9) | 4.8(3.6,6.9) | -0.055 | 0.956 |
ACTH(16:00)[M(Q1,Q3),pmol/L] | 3.6(2.6,4.8) | 3.8(2.5,5.2) | -0.323 | 0.747 |
ACTH(24:00)[M(Q1,Q3),pmol/L] | 2.0(1.4,3.0) | 2.1(1.4,3.0) | -0.457 | 0.648 |
皮质醇(8:00)[M(Q1,Q3),nmol/L] | 394.7(303.9,495.7) | 387.5(285.2,470.4) | -0.282 | 0.778 |
皮质醇(16:00)[M(Q1,Q3),nmol/L] | 214.0(158.2,283.7) | 207.7(160.6,276.3) | -0.483 | 0.629 |
皮质醇(24:00)[M(Q1,Q3),nmol/L] | 81.4(53.0,130.0) | 81.3(52.0,130.4) | -0.053 | 0.958 |
Table 1 Comparison of clinical indicators between the training set and validation set
指标 | 训练集(n=633) | 验证集(n=272) | Z(χ2)值 | P值 |
---|---|---|---|---|
年龄[M(Q1,Q3),岁] | 59(53,63) | 58(51,64) | -0.232 | 0.817 |
性别[例(%)] | 0.300a | 0.584 | ||
男 | 343(54.2) | 142(52.2) | ||
女 | 290(45.8) | 130(47.8) | ||
肌肉量减少[例(%)] | 278(43.9) | 105(38.6) | 2.202a | 0.138 |
病程[M(Q1,Q3),年] | 10(4,15) | 9(5,15) | -0.928 | 0.353 |
BMI<23.5 kg/m2[例(%)] | 292(46.1) | 117(43.0) | 0.745a | 0.388 |
SBP[M(Q1,Q3),mmHg] | 133(119,146) | 135(124,146) | -1.232 | 0.218 |
DBP[M(Q1,Q3),mmHg] | 81(74,89) | 82(75,88) | -0.547 | 0.584 |
ALT[M(Q1,Q3),U/L] | 17.5(13.6,24.3) | 18.9(13.4,26.8) | -0.993 | 0.321 |
AST[M(Q1,Q3),U/L] | 16.5(14.1,20.9) | 17.4(14.1,22.4) | -1.397 | 0.162 |
GGT[M(Q1,Q3),U/L] | 24.5(16.9,37.7) | 25.4(18.8,38.7) | -1.402 | 0.161 |
HbA1c[M(Q1,Q3),%] | 8.6(7.2,10.2) | 8.9(7.3,10.2) | -1.135 | 0.256 |
FBG[M(Q1,Q3),mmol/L] | 7.9(6.3,9.9) | 7.8(6.5,9.8) | -0.456 | 0.648 |
FINS[M(Q1,Q3),μU/mL] | 5.5(3.4,8.9) | 5.5(3.4,8.8) | -0.012 | 0.990 |
HOMA-IR[M(Q1,Q3)] | 2.0(1.2,3.3) | 2.0(1.2,3.2) | -0.029 | 0.977 |
TG[M(Q1,Q3),mmol/L] | 1.3(1.0,1.9) | 1.3(0.9,1.8) | -0.552 | 0.581 |
TC[M(Q1,Q3),mmol/L] | 4.5(3.8,5.4) | 4.6(3.8,5.4) | -0.899 | 0.369 |
HDL-C[M(Q1,Q3),mmol/L] | 1.2(1.0,1.4) | 1.2(1.0,1.4) | -0.210 | 0.834 |
LDL-C[M(Q1,Q3),mmol/L] | 2.7(2.0,3.4) | 2.7(2.1,3.5) | -0.821 | 0.412 |
UA[M(Q1,Q3),μmol/L] | 305.5(251.0,371.3) | 309.0(259.0,371.0) | -0.114 | 0.909 |
Scr[M(Q1,Q3),μmol/L] | 56.0(45.0,66.0) | 57.0(49.3,66.8) | -1.617 | 0.106 |
eGFR[M(Q1,Q3),mL·min-1·(1.73 m2)-1] | 124.8(104.8,146.2) | 120.6(103.8,140.6) | -1.021 | 0.307 |
CRP[M(Q1,Q3),mg/L] | 2.9(2.1,3.9) | 2.7(2.0,3.8) | -1.088 | 0.277 |
OCN[M(Q1,Q3),ng/mL] | 12.2(9.5,15.6) | 12.0(9.4,15.5) | -0.104 | 0.917 |
β-CTX[M(Q1,Q3),ng/mL] | 0.4(0.3,0.5) | 0.4(0.3,0.5) | -0.208 | 0.835 |
P1ND[M(Q1,Q3),ng/mL] | 37.1(27.8,49.1) | 36.8(29.5,49.0) | -0.377 | 0.706 |
25(OH)D3[M(Q1,Q3),ng/mL] | 19.7(15.4,24.5) | 19.6(15.1,24.5) | -0.172 | 0.864 |
ALB[M(Q1,Q3),g/L] | 42.1(40.3,43.5) | 42.2(40.6,43.6) | -1.322 | 0.186 |
Hb[M(Q1,Q3),g/L] | 141(131,151) | 143(133,152) | -1.607 | 0.108 |
UACR[M(Q1,Q3),mg/g] | 12.0(6.7,28.7) | 11.7(7.4,23.9) | -0.248 | 0.804 |
内脏脂肪面积[M(Q1,Q3),cm2] | 79.6(65.1,97.8) | 78.6(64.5,95.7) | -0.540 | 0.589 |
TSH[M(Q1,Q3),mU/L] | 1.7(1.2,2.5) | 1.7(1.2,2.4) | -0.579 | 0.572 |
FT3[M(Q1,Q3),pmol/L] | 4.4(4.0,4.8) | 4.5(4.1,4.9) | -1.554 | 0.119 |
FT4[M(Q1,Q3),pmol/L] | 17.1(15.6,19.0) | 17.2(15.7,19.0) | -0.703 | 0.482 |
GH[M(Q1,Q3),μg/L] | 0.4(0.1,1.2) | 0.4(0.1,1.2) | -0.987 | 0.324 |
ACTH(8:00)[M(Q1,Q3),pmol/L] | 4.9(3.4,6.9) | 4.8(3.6,6.9) | -0.055 | 0.956 |
ACTH(16:00)[M(Q1,Q3),pmol/L] | 3.6(2.6,4.8) | 3.8(2.5,5.2) | -0.323 | 0.747 |
ACTH(24:00)[M(Q1,Q3),pmol/L] | 2.0(1.4,3.0) | 2.1(1.4,3.0) | -0.457 | 0.648 |
皮质醇(8:00)[M(Q1,Q3),nmol/L] | 394.7(303.9,495.7) | 387.5(285.2,470.4) | -0.282 | 0.778 |
皮质醇(16:00)[M(Q1,Q3),nmol/L] | 214.0(158.2,283.7) | 207.7(160.6,276.3) | -0.483 | 0.629 |
皮质醇(24:00)[M(Q1,Q3),nmol/L] | 81.4(53.0,130.0) | 81.3(52.0,130.4) | -0.053 | 0.958 |
变量 | 单因素Logistic回归分析 | 多因素Logistic回归分析 | ||
---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | |
年龄 | 1.034(1.013~1.056) | 0.002 | 1.039(1.010~1.070) | 0.009 |
男性(以女性为参考) | 1.452(1.057~1.994) | 0.021 | 3.425(2.133~5.499) | <0.001 |
病程 | 1.015(0.992~1.038) | 0.207 | ||
BMI<23.5 kg/m2(以≥23.5 kg/m2为参考) | 8.651(6.033~12.403) | <0.001 | 19.678(11.319~34.210) | <0.001 |
SBP | 0.991(0.983~1.000) | 0.039 | ||
DBP | 0.989(0.976~1.003) | 0.122 | ||
ALT | 1.001(0.997~1.006) | 0.486 | ||
AST | 1.006(0.995~1.017) | 0.303 | ||
GGT | 1.000(0.996~1.005) | 0.886 | ||
HbA1c | 1.169(1.082~1.262) | <0.001 | 1.196(1.081~1.323) | <0.001 |
FBG | 1.020(0.967~1.077) | 0.469 | ||
FINS | 0.972(0.944~1.001) | 0.059 | ||
HOMA-IR | 0.952(0.892~1.016) | 0.138 | ||
TG | 0.888(0.770~1.025) | 0.104 | ||
TC | 1.037(0.920~1.169) | 0.556 | ||
HDL-C | 1.190(0.742~1.909) | 0.470 | ||
LDL-C | 1.103(0.945~1.289) | 0.215 | ||
UA | 1.000(0.998~1.002) | 0.871 | ||
Scr | 1.004(0.998~1.007) | 0.335 | ||
eGFR | 1.002(0.998~1.006) | 0.335 | ||
CRP | 1.004(0.994~1.015) | 0.399 | ||
OCN | 1.011(0.984~1.038) | 0.449 | ||
β-CTX | 1.831(0.914~3.669) | 0.088 | ||
P1ND | 1.001(0.993~1.008) | 0.858 | ||
25(OH)D3 | 0.988(0.966~1.011) | 0.310 | ||
ALB | 0.929(0.874~0.988) | 0.019 | ||
Hb | 1.009(0.998~1.020) | 0.095 | ||
UACR | 1.000(1.000~1.001) | 0.506 | ||
内脏脂肪面积 | 0.989(0.983~0.996) | 0.002 | 1.021(1.010~1.032) | <0.001 |
TSH | 0.929(0.836~1.033) | 0.174 | ||
FT3 | 0.933(0.806~1.080) | 0.354 | ||
FT4 | 1.008(0.952~1.067) | 0.788 | ||
GH | 1.069(0.966~1.184) | 0.196 | ||
ACTH(8:00) | 1.040(0.991~1.091) | 0.113 | ||
ACTH(16:00) | 0.982(0.910~1.058) | 0.628 | ||
ACTH(24:00) | 1.016(0.933~1.105) | 0.720 | ||
皮质醇(8:00) | 1.001(1.000~1.003) | 0.010 | ||
皮质醇(16:00) | 1.000(0.999~1.002) | 0.493 | ||
皮质醇(24:00) | 1.001(0.998~1.003) | 0.197 |
Table 2 Univariate and multivariate Logistic regression analyses of muscle mass loss in non-obese patients with T2DM in the training set
变量 | 单因素Logistic回归分析 | 多因素Logistic回归分析 | ||
---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | |
年龄 | 1.034(1.013~1.056) | 0.002 | 1.039(1.010~1.070) | 0.009 |
男性(以女性为参考) | 1.452(1.057~1.994) | 0.021 | 3.425(2.133~5.499) | <0.001 |
病程 | 1.015(0.992~1.038) | 0.207 | ||
BMI<23.5 kg/m2(以≥23.5 kg/m2为参考) | 8.651(6.033~12.403) | <0.001 | 19.678(11.319~34.210) | <0.001 |
SBP | 0.991(0.983~1.000) | 0.039 | ||
DBP | 0.989(0.976~1.003) | 0.122 | ||
ALT | 1.001(0.997~1.006) | 0.486 | ||
AST | 1.006(0.995~1.017) | 0.303 | ||
GGT | 1.000(0.996~1.005) | 0.886 | ||
HbA1c | 1.169(1.082~1.262) | <0.001 | 1.196(1.081~1.323) | <0.001 |
FBG | 1.020(0.967~1.077) | 0.469 | ||
FINS | 0.972(0.944~1.001) | 0.059 | ||
HOMA-IR | 0.952(0.892~1.016) | 0.138 | ||
TG | 0.888(0.770~1.025) | 0.104 | ||
TC | 1.037(0.920~1.169) | 0.556 | ||
HDL-C | 1.190(0.742~1.909) | 0.470 | ||
LDL-C | 1.103(0.945~1.289) | 0.215 | ||
UA | 1.000(0.998~1.002) | 0.871 | ||
Scr | 1.004(0.998~1.007) | 0.335 | ||
eGFR | 1.002(0.998~1.006) | 0.335 | ||
CRP | 1.004(0.994~1.015) | 0.399 | ||
OCN | 1.011(0.984~1.038) | 0.449 | ||
β-CTX | 1.831(0.914~3.669) | 0.088 | ||
P1ND | 1.001(0.993~1.008) | 0.858 | ||
25(OH)D3 | 0.988(0.966~1.011) | 0.310 | ||
ALB | 0.929(0.874~0.988) | 0.019 | ||
Hb | 1.009(0.998~1.020) | 0.095 | ||
UACR | 1.000(1.000~1.001) | 0.506 | ||
内脏脂肪面积 | 0.989(0.983~0.996) | 0.002 | 1.021(1.010~1.032) | <0.001 |
TSH | 0.929(0.836~1.033) | 0.174 | ||
FT3 | 0.933(0.806~1.080) | 0.354 | ||
FT4 | 1.008(0.952~1.067) | 0.788 | ||
GH | 1.069(0.966~1.184) | 0.196 | ||
ACTH(8:00) | 1.040(0.991~1.091) | 0.113 | ||
ACTH(16:00) | 0.982(0.910~1.058) | 0.628 | ||
ACTH(24:00) | 1.016(0.933~1.105) | 0.720 | ||
皮质醇(8:00) | 1.001(1.000~1.003) | 0.010 | ||
皮质醇(16:00) | 1.000(0.999~1.002) | 0.493 | ||
皮质醇(24:00) | 1.001(0.998~1.003) | 0.197 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
罗琴,苟连平,陈银,等. 小腿围、上臂围和Ishii评分对冠心病合并肌少症患者的诊断价值比较[J/OL]. 中国全科医学,2023. [2024-02-17].
|
[11] |
|
[12] |
|
[13] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志,2021,37(4):311-398. DOI:10.3760/cma.j.cn311282-20210304-00142.
|
[14] |
|
[15] |
|
[16] |
段明,张欣欣,孔悠然,等. 2型糖尿病患者肌肉量减少的多因素分析[J]. 中华内分泌代谢杂志,2020,36(9):778-782. DOI:10.3760/cma.j.cn311282-20191123-00512.
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[1] | JIA Gaopeng, CHEN Qiuyu. Construction and Validation of a Risk Prediction Model for Recurrent Angina after Percutaneous Coronary Intervention in Elderly Patients with Acute ST-segment Elevation Myocardial Infarction: Based on CYP2C19-related Genetic Testing [J]. Chinese General Practice, 2025, 28(30): 3779-3786. |
[2] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
[3] | SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374. |
[4] | ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877. |
[5] | ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783. |
[6] | GUO Shengteng, ZHANG Fenfen, WAN Di, YU Dongmei, WANG Qinghua. Risk Factors for Severe Acute Pancreatitis Complicated with Acute Lung Injury: a Meta-analysis [J]. Chinese General Practice, 2025, 28(20): 2546-2554. |
[7] | LI Bing, XI Zhi, WANG Yang, XIU Jiaqi, GUO Qiancheng, YU Chenchen, SUN Siyu, YANG Xiaopeng. Association of Blood Pressure Variability and Systemic Immune-inflammation Index with Intracranial Arterial Negative Remodeling in Patients with Cerebral Small Vessel Disease [J]. Chinese General Practice, 2025, 28(14): 1751-1757. |
[8] | WANG Xiaoyu, FENG Zhenzhen, WANG Jun, GUO Xiaochuan, LI Jiansheng. Risk Factors for Acute Kidney Injury in Acute Respiratory Distress Syndrome: a Systematic Review [J]. Chinese General Practice, 2025, 28(12): 1527-1537. |
[9] | LIAO Xingyu, TIAN Siyu, CHEN Min. The Disease Burden, Risk Factors and Predictive Analysis of Early-onset Colorectal Cancer of Different Genders between China and the World from 1990 to 2021 [J]. Chinese General Practice, 2025, 28(08): 1004-1011. |
[10] | ZOU Songyan, ZHANG Riyi, LI Xiaodong, MU Yinyu. Analysis of Clinical Characteristics and Risk Factors of Systemic Sclerosis Combined with Sjögren's Syndrome [J]. Chinese General Practice, 2025, 28(06): 737-741. |
[11] | SHI Xiaotian, WANG Shan, YANG Huayu, YANG Yifan, LI Xu, DOU Guoze, MA Qing. A Predictive Nomogram for the Risk of Frailty/Pre-frailty on Inflammatory Biomarkers in the Elderly [J]. Chinese General Practice, 2025, 28(05): 587-593. |
[12] | KONG Linghong, XIE Xiaoxin, FU Yanhua, GAN Lin, YANG Xiaoyan, MA Shujing, LONG Hai. Pre-treatment and Acquired Antiretroviral Drug Resistance among People Living with HIV in Southwest China [J]. Chinese General Practice, 2025, 28(02): 242-249. |
[13] | LIU Mingbo, HE Xinye, YANG Xiaohong, WANG Zengwu. Interpretation of Report on Cardiovascular Health and Diseases in China 2023 [J]. Chinese General Practice, 2025, 28(01): 20-38. |
[14] | TAO Jintao, WU Shouling, ZHAO Xiaohong. Prevalence and Risk Factors of Atrioventricular Block in the Population: a Study Based on the Kailuan Cohort [J]. Chinese General Practice, 2024, 27(36): 4534-4539. |
[15] | GU Shanye, ZHOU Ziyi, CAI Yefeng. Study on Risk Prediction of Non-dementia Vascular Cognitive Impairment in Glycolipid Metabolic Diseases [J]. Chinese General Practice, 2024, 27(35): 4412-4416. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||